DBV Technologies (DBVT) Projected to Post Earnings on Thursday

03 Mar 2026, 04:13 by Amy Steele · The Cerbat Gem

DBV Technologies (NASDAQ:DBVT – Get Free Report) is projected to release its Q4 2025 results before the market opens on Thursday, March 5th. Analysts expect DBV Technologies to post earnings of ($0.1935) per share and revenue of $1.0570 million for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, March 12, 2026 at 7:00 AM ET.

DBV Technologies Price Performance

DBV Technologies stock opened at $23.25 on Tuesday. The stock has a market cap of $1.28 billion, a P/E ratio of -4.50 and a beta of -0.97. The firm’s 50 day moving average price is $20.68 and its 200-day moving average price is $15.83. DBV Technologies has a 1 year low of $3.82 and a 1 year high of $26.18.

Insider Transactions at DBV Technologies

In other DBV Technologies news, major shareholder Bpifrance Epic sold 2,076,990 shares of the company’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $4.85, for a total value of $10,073,401.50. Following the sale, the insider owned 8,595,472 shares in the company, valued at approximately $41,688,039.20. This represents a 19.46% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders sold 3,369,627 shares of company stock valued at $15,489,908 over the last three months. Insiders own 1.44% of the company’s stock.

Hedge Funds Weigh In On DBV Technologies

Several large investors have recently made changes to their positions in DBVT. Truvestments Capital LLC raised its holdings in DBV Technologies by 71.3% in the 4th quarter. Truvestments Capital LLC now owns 3,892 shares of the company’s stock worth $75,000 after purchasing an additional 1,620 shares during the period. Royal Bank of Canada purchased a new position in DBV Technologies in the 4th quarter valued at $34,000. Persistent Asset Partners Ltd acquired a new position in DBV Technologies during the fourth quarter worth about $115,000. Cetera Investment Advisers acquired a new position in shares of DBV Technologies during the 4th quarter worth approximately $251,000. Finally, Two Sigma Investments LP purchased a new stake in shares of DBV Technologies in the third quarter valued at approximately $167,000. 71.74% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have weighed in on DBVT shares. Citizens Jmp raised their price target on DBV Technologies from $21.00 to $45.00 and gave the company a “market outperform” rating in a report on Wednesday, December 17th. Citigroup reaffirmed an “outperform” rating on shares of DBV Technologies in a research report on Wednesday, December 17th. Wall Street Zen raised shares of DBV Technologies from a “sell” rating to a “hold” rating in a research report on Sunday, February 8th. Cantor Fitzgerald set a $48.00 price objective on shares of DBV Technologies in a research note on Wednesday, December 17th. Finally, Guggenheim reiterated a “buy” rating and issued a $51.00 price target (up from $35.00) on shares of DBV Technologies in a report on Wednesday, December 17th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $38.25.

Get Our Latest Report on DBV Technologies

DBV Technologies Company Profile

(Get Free Report)

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.